SG11201502104YA - Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium - Google Patents

Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium

Info

Publication number
SG11201502104YA
SG11201502104YA SG11201502104YA SG11201502104YA SG11201502104YA SG 11201502104Y A SG11201502104Y A SG 11201502104YA SG 11201502104Y A SG11201502104Y A SG 11201502104YA SG 11201502104Y A SG11201502104Y A SG 11201502104YA SG 11201502104Y A SG11201502104Y A SG 11201502104YA
Authority
SG
Singapore
Prior art keywords
trospium
treatment
methods
drug delivery
delivery systems
Prior art date
Application number
SG11201502104YA
Other languages
English (en)
Inventor
Dennis Giesing
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of SG11201502104YA publication Critical patent/SG11201502104YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
SG11201502104YA 2012-09-18 2013-09-18 Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium SG11201502104YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702576P 2012-09-18 2012-09-18
PCT/US2013/060479 WO2014047221A1 (en) 2012-09-18 2013-09-18 Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium

Publications (1)

Publication Number Publication Date
SG11201502104YA true SG11201502104YA (en) 2015-05-28

Family

ID=49301639

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502104YA SG11201502104YA (en) 2012-09-18 2013-09-18 Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium

Country Status (13)

Country Link
US (2) US10500200B2 (enExample)
EP (1) EP2897616A1 (enExample)
JP (2) JP6600256B2 (enExample)
KR (1) KR102141433B1 (enExample)
CN (2) CN104684556A (enExample)
AU (1) AU2013318146B2 (enExample)
BR (1) BR112015005351A2 (enExample)
CA (1) CA2883855C (enExample)
IL (1) IL237498B (enExample)
MX (2) MX379066B (enExample)
RU (1) RU2670749C9 (enExample)
SG (1) SG11201502104YA (enExample)
WO (1) WO2014047221A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
BR112015004110A2 (pt) 2012-08-31 2017-07-04 Taris Biomedical Llc sistemas e métodos de distribuição de drogas para tratamento de próstata
SI2890384T1 (sl) 2012-08-31 2022-02-28 Taris Biomedical Llc Sistemi za dostavo zdravila in postopki za zdravljenje raka sečnega mehurja, ki obsegajo oksaliplatin
SG11201502104YA (en) * 2012-09-18 2015-05-28 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium
US20150250717A1 (en) 2014-03-06 2015-09-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
WO2016028774A1 (en) * 2014-08-19 2016-02-25 The Regents Of The University Of California Implants for localized drug delivery and methods of use thereof
GB201506526D0 (en) 2015-04-17 2015-06-03 Uropharma Ltd And Synesis Llc Medicinal composition
CN106706832A (zh) * 2015-08-06 2017-05-24 舒泰神（北京）生物制药股份有限公司 一种测定曲司氯铵含量的方法
SMT202100310T1 (it) 2017-02-01 2021-07-12 Taris Biomedical Llc Dispositivi per la deposizione di farmaci in vivo
US10857173B2 (en) 2017-07-25 2020-12-08 Taris Biomedical Llc Methods of treating tumor metastasis
JOP20200124A1 (ar) 2017-11-08 2020-05-20 Taris Biomedical Llc طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
JP7460608B2 (ja) 2018-05-07 2024-04-02 ジェンマブ エー／エス 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法
KR20210039403A (ko) 2018-08-01 2021-04-09 타리스 바이오메디컬 엘엘씨 트로스피움을 사용한 과민성 방광의 치료 방법
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
EP3962449A1 (en) * 2019-04-30 2022-03-09 Trigone Pharma Ltd Formulations and methods for drug instillation into the bladder and treatment of bladder ailments
CA3171976A1 (en) 2020-03-20 2021-09-23 Carlos Schuler Implantable drug delivery devices for localized drug delivery
US11338119B2 (en) 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
KR102596697B1 (ko) 2021-05-20 2023-11-01 김정우 바위솔 추출물을 유효성분으로 포함하는 화장품 조성물 및 그 제조 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2125696T3 (es) * 1996-11-27 1999-03-01 Pfleger R Chem Fab Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
US20060058777A1 (en) * 2002-12-11 2006-03-16 Pia Norup Nielsen Urinary catheter device with a pharmaceutically active composition
CA2513188A1 (en) 2003-01-16 2004-08-05 University Of Rochester Quaternary antimuscarinic compounds for the treatment of bladder diseases
ES2322148T3 (es) 2004-08-11 2009-06-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias.
US20060217405A1 (en) * 2005-03-17 2006-09-28 Indevus Pharmaceuticals, Inc. Interstitial cystitis treatment
US7390816B2 (en) 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
JP5265359B2 (ja) 2005-08-11 2013-08-14 マサチューセッツ インスティテュート オブ テクノロジー 膀胱内薬物送達デバイスおよび方法
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
US9586035B2 (en) 2007-12-11 2017-03-07 Massachusetts Institute Of Technology Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
EA201170297A1 (ru) 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
AU2010265863C1 (en) 2009-06-26 2012-11-01 Taris Biomedical Llc Implantable drug delivery devices and methods of making the same
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
AU2010339821B2 (en) 2009-12-17 2015-02-19 Taris Biomedical Llc Implantable device with intravesical tolerability and methods of treatment
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
JP5945544B2 (ja) * 2010-10-06 2016-07-05 タリス バイオメディカル エルエルシー 時間選択的に生体吸収可能または崩壊可能な薬剤送達システムおよび方法
WO2012048104A1 (en) 2010-10-06 2012-04-12 Taris Biomedical, Inc. Implantable drug delivery device with bladden retention feature
CA2823783C (en) 2011-01-10 2023-03-21 Taris Biomedical, Inc. Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
RU2598057C2 (ru) * 2011-02-04 2016-09-20 ТАРИС Биомедикал ЛЛК Имплантируемое устройство для контролируемого высвобождения лекарственного средства с низкой растворимостью
SG11201502104YA (en) * 2012-09-18 2015-05-28 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium
HUE072250T2 (hu) 2013-03-15 2025-11-28 Taris Biomedical Llc Gyógyszeradagoló eszközök gyógyszeráteresztõ résszel

Also Published As

Publication number Publication date
RU2015112196A (ru) 2016-11-10
CA2883855C (en) 2020-09-15
WO2014047221A9 (en) 2015-05-21
MX379066B (es) 2025-03-04
RU2670749C9 (ru) 2018-12-13
JP2015529688A (ja) 2015-10-08
US20200108057A1 (en) 2020-04-09
KR20150058271A (ko) 2015-05-28
WO2014047221A1 (en) 2014-03-27
AU2013318146A1 (en) 2015-03-19
IL237498B (en) 2018-01-31
JP2018080208A (ja) 2018-05-24
EP2897616A1 (en) 2015-07-29
CA2883855A1 (en) 2014-03-27
JP6600256B2 (ja) 2019-10-30
MX2020002465A (es) 2020-07-13
RU2670749C2 (ru) 2018-10-25
CN111450093A (zh) 2020-07-28
AU2013318146B2 (en) 2018-05-10
US10500200B2 (en) 2019-12-10
CN104684556A (zh) 2015-06-03
KR102141433B1 (ko) 2020-08-05
IL237498A0 (en) 2015-04-30
MX2015003110A (es) 2015-06-05
US11850244B2 (en) 2023-12-26
BR112015005351A2 (pt) 2017-07-04
US20150182516A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
IL237498A0 (en) Drug delivery systems and methods for treating bladder emptying dysfunction and other lower urinary tract disorders using tropesium
IL274469A (en) Compositions, uses and methods for the treatment of metabolic disorders and diseases
EP2785275A4 (en) TREATMENT OF HARNINE CONTINENCE
EP2675402A4 (en) BLOOD FLOW INTERFERENCE DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DEFECTS
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
EP2731658A4 (en) DEVICE FOR DISTRIBUTING ANTIMICROBIAL AGENT IN TRANSDERMAL CATHETER
AU339607S (en) Medical device for treatment of sleep disorders
IL239557B (en) Microarray for providing therapeutic material and methods for use
PT2600800T (pt) Dispositivo de administração de drogas por stent ureteral, kit e método
EP2782631A4 (en) IMPLANTABLE APPARATUS FOR USE IN THE ADMINISTRATION OF A SOLID-LIQUID MEDICAMENT, ASSOCIATED FORMULATIONS AND METHODS OF USE
AP2013007178A0 (en) BCMA-based stratification and therapy for multiplemyeloma patients
IL227312A0 (en) Lidocaine administration regimen for long-term treatment of bladder pain and voiding irritation
IL237281A0 (en) Drug delivery systems and methods for treating bladder cancer comprising oxaliplatin
IL254446A0 (en) Implantable drug delivery preparations and treatment methods thereof
IL237300B (en) Drug delivery systems and methods for treating prostate gland diseases containing gemcitabine
GB2496688B (en) Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
EP2553639A4 (en) SYSTEMS AND METHODS FOR MANAGING THE TREATMENT OF ORPHAN DISEASE
EP2790637A4 (en) VAGINAL DRUG DELIVERY DEVICES AND METHODS OF MANUFACTURING THE SAME
PT2774991T (pt) Sistema de entrega de fármaco para utilização no tratamento ou diagnóstico de distúrbios neurológicos
ZA201502288B (en) Ciclesonide for treatment of airway disease in horses
EP2763716A4 (en) SOLID MEDICATION ADMINISTRATION APPARATUS, FORMULATIONS AND METHODS OF USE
WO2012158942A9 (en) Drug treatment of overactive bladder
IL239308A0 (en) Treatment of diseases of endothelial dysfunction and inflammation
EP2673372A1 (en) Methods of prognosing and administering treatment for inflammatory disorders
IL227921A0 (en) Methods for prognosis and treatment of inflammatory disorders